Herpesin Forte (Aciclovir)

Herpesin Forte is prescribed for the treatment and management of infections caused by herpes viruses, providing antiviral activity that reduces viral replication and symptom severity.

• Mild to moderate oral herpes simplex (cold‑sore) outbreaks with vesicular lesions on the lips.
• Genital herpes infections caused by HSV‑1 or HSV‑2, including primary and recurrent lesions.
• Herpes zoster (shingles) affecting a dermatome, presenting with painful vesicular rash.
• Suppressive therapy to lower frequency and severity of recurrent herpes simplex episodes.
• Post‑exposure prophylaxis for individuals with known HSV exposure, particularly immunocompromised patients.

• Aciclovir, the active component of Herpesin Forte, is a nucleoside analogue that is selectively phosphorylated by viral thymidine kinase. The resulting aciclovir monophosphate is further converted by cellular kinases to the active triphosphate form, which competitively inhibits viral DNA polymerase. This inhibition blocks the elongation of viral DNA chains, preventing viral replication while having minimal effect on host cellular DNA synthesis.

Herpesin Forte may cause adverse reactions, most of which are mild and transient, while rare serious events have been reported.

Common

• Nausea, vomiting, or abdominal discomfort, usually mild and transient.
• Headache or dizziness that often improves with continued use.
• Mild skin rash or itching without systemic signs.
• Temporary rise in liver enzymes observed in lab tests.

Serious

• Severe allergic reactions such as anaphylaxis or angioedema requiring immediate medical attention.
• Acute renal impairment, especially in dehydrated patients or those with pre‑existing kidney disease.
• Blood‑cell abnormalities like neutropenia or thrombocytopenia that may need drug discontinuation.

When prescribing Herpesin Forte, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

• Assess renal function before initiation and adjust dose in patients with impaired clearance.
• Use caution in individuals with known hypersensitivity to aciclovir or related nucleoside analogues.
• Monitor liver function tests during prolonged therapy, especially in patients with hepatic disease.
• Evaluate for concurrent use of nephrotoxic drugs such as aminoglycosides or NSAIDs.
• Consider pregnancy and breastfeeding status; data are limited, so risk‑benefit assessment is essential.
• Advise patients to maintain adequate hydration to reduce renal toxicity risk.

Herpesin Forte can interact with other medicines, affecting its effectiveness or increasing toxicity; awareness of these interactions helps optimize therapy.

Avoid

• Concomitant use with probenecid, which markedly reduces aciclovir renal clearance.
• Co‑administration with nephrotoxic agents such as cisplatin or high‑dose intravenous contrast media.
• Simultaneous therapy with other antiviral nucleoside analogues that may compound toxicity.

Use with caution

• Concurrent use of non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function.
• Combination with immunosuppressants (e.g., azathioprine) requiring closer monitoring of blood counts.
• Use alongside drugs that alter gastric pH, such as proton‑pump inhibitors, which may affect absorption.